2,514 resources
Start Prev Rows 2200 - 2400 Next
Package | Version | Identity | Name/Title | Status | FMM | WG | Date | Realm |
---|---|---|---|---|---|---|---|---|
smart.who.int.hiv | R4 | ValueSet/HIV.H.DE13 | Contact method ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.E.DE52 | Delivery mode ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.E.DE246 | Blood group and Rh factor ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE399 | Monitoring examinations ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE52 | Facility transferred from ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.H.DE50 | Transfer to facility ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE120 | Site where positive HIV test confirmed ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE457 | Medications prescribed ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE485 | New regimen after switch to second-line regimen ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE491 | New regimen after switch to third-line regimen ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE489 | New regimen(s) after substitution within second-line regimen ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE495 | New regimen(s) after substitution within third-line regimen ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE483 | New antiretroviral regimen after substitution within first-line regimen ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE289 | WHO HIV clinical stage condition or symptom ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE934 | WHO HIV clinical stage condition or symptom ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE172 | Other support services ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.C.DE164 | Other support services ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE519 | Other support services ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE152 | Prevention services offered and referrals ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE149 | Prevention services offered and referrals ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.C.DE131 | Prevention services offered and referrals ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE158 | Sexual and reproductive health integrated services ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.C.DE149 | Sexual and reproductive health integrated services ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE156 | Sexual and reproductive health integrated services ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE74 | Original first-line ART regimen ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE165 | Offer other clinical services ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.C.DE157 | Offer other clinical services ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE753 | Offer other clinical services ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.Config.DE19 | Other priority populations ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.E.DE47 | Pregnancy outcome ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.C.DE80 | PrEP product prescribed ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.C.DE91 | Preferred PEP backbone regimen ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.C.DE99 | Preferred third PEP drug ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE121 | Probable route of transmission ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE217 | Reason ART stopped ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE1 | Reason for visit ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE636 | Reason immunization was not provided ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE370 | Reasons for delayed ART initiation ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.G.DE22 | Reason Hepatitis B test not conducted ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.G.DE35 | Reason Hepatitis C test not done ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE418 | Reason for ARV drug regimen substitution ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE430 | Reason for regimen switch ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.G.DE62 | Reason syphilis test not done ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.H.DE74 | Reason ART stopped ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.H.DE53 | Reason(s) for adherence problem ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE197 | Reason(s) for adherence problem ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE486 | Reason for switch to second-line regimen ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE492 | Reason for switch to third-line regimen ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE532 | Reason blood pressure reading not done ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.I.DE2 | Reason for referral ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE646 | Reason malaria prophylaxis not provided ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE488 | Reason(s) for substitution within second-line regimen ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE494 | Reason(s) for substitution within third-line regimen ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE482 | Reason(s) for substitution within first-line regimen ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE986 | TB screening result ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE256 | Gonorrhoea test result ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE808 | Gonorrhoea test result ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE312 | STI test result ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE864 | STI test result ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE325 | Confirmatory STI test result ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE877 | Confirmatory STI test result ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.E.DE149 | Maternal syphilis test result ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE250 | Syphilis test result ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE802 | Syphilis test result ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.G.DE70 | Syphilis test result ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE691 | Cervical cancer colposcopy result ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE697 | Cervical cancer histopathology result ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE179 | Intimate partner violence enquiry results ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.E.DE255 | Asymptomatic bacteriuria (ASB) test result ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE44 | HIV self-test result ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.E.DE259 | Urine protein test result ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE237 | STI tested for ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE956 | TB screening algorithm ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE673 | Cervical cytology screening test result ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE668 | VIA cervical cancer screening test result ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE201 | Adverse event severity ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.A.DE25 | Sex ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE259 | Risk factors, comorbidities and coinfections signs and symptoms ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE17 | Signs of serious illness ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.C.DE36 | Signs of substantial risk of HIV infection ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.E.DE155 | Signs of substantial risk of HIV infection ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.H.DE17 | Source of information ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE18 | Entry point for community-level testing ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE22 | Entry point for facility-level testing ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE746 | Entry point for facility-level testing ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE893 | Staging of liver disease ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.C.DE46 | Acute HIV infection symptoms ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE973 | Symptoms of TB ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE226 | Syndrome/STI diagnosed ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE778 | Syndrome/STI diagnosed ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE1010 | TB treatment regimen composition ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.E.DE104 | Maternal HIV test result ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE688 | HPV16/18 test result ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE136 | Partner HIV status (confirmed) ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.PRV.DE11 | HIV status of contact ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE33 | Partner HIV status (reported) ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.E.DE141 | Maternal HIV status ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.E.DE145 | Maternal HIV status at first ANC visit ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE132 | Partner HIV test result ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE78 | Alternative first-line ART regimen ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE81 | Alternative second-line ART regimen ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE603 | Vaccine brand ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE68 | HIV serotype ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.C.DE24 | Experience with PrEP ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.C.DE31 | PEP history ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE75 | Current ART regimen ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE66 | HIV diagnosing facility ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE79 | First-line ART regimen under special circumstances ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.E.DE240 | Cause of death of infant ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE88 | Assay number in testing strategy ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.E.DE194 | Assay number in testing strategy ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE82 | Optimal regimen for transition ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.H.DE41 | HIV treatment outcome ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.E.DE234 | HIV-exposed infant reason for unknown final status ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE77 | Preferred first-line ART regimen ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE80 | Preferred second-line ART regimen ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.H.DE1 | Reason for follow-up ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE111 | HIV test result ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE94 | Test result of HIV assay 1 ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.E.DE200 | Test result of HIV assay 1 ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.E.DE216 | Test result of syphilis assay 1 ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.E.DE220 | Test result of syphilis assay 1 repeated ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE106 | Test result of HIV assay 1 repeated ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.E.DE212 | Test result of HIV assay 1 repeated ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE98 | Test result of HIV assay 2 ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.E.DE204 | Test result of HIV assay 2 ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE102 | Test result of HIV assay 3 ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.E.DE208 | Test result of HIV assay 3 ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE606 | Vaccination location ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE992 | TB diagnostic test category ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE50 | Key population member type ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.E.DE114 | Key population member type ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.E.DE67 | Place of delivery ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.G.DE13 | HIV viral load specimen type ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.E.DE62 | Preterm birth status ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.E.DE75 | Cause of death of mother ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.A.DE43 | Administrative Area ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE383 | Time to start ART ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.C.DE55 | Sex partner's HIV treatment status ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE719 | Treatment method for cervical precancer lesions ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE764 | DSD ART model(s) ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE81 | HIV test type ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.E.DE168 | HIV test type ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE1028 | TPT regimen type ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE207 | Type of adverse VMMC event ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE709 | Cervical cancer diagnosis ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE658 | Cervical cancer primary screening test type ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.C.DE138 | Condom type ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE284 | Chlamydia trachomatis test type ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE836 | Chlamydia trachomatis test type ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE853 | Herpes simplex virus (HSV) test type ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE306 | Mycoplasma genitalium test type ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE858 | Mycoplasma genitalium test type ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE276 | Neisseria gonorrhoeae test type ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE828 | Neisseria gonorrhoeae test type ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE293 | Trichomonas vaginalis test type ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE845 | Trichomonas vaginalis test type ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE301 | Herpes simplex virus (HSV) test type ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE821 | Syphilis test type ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE269 | Syphilis test type ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.G.DE55 | Syphilis test type ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE191 | Type of follow-up appointment ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.C.DE125 | Type of follow-up appointment ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.E.DE264 | Type of hypertensive disorder ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE182 | HCV medicine type ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE261 | Type of specimen ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE813 | Type of specimen ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE317 | Confirmatory syphilis test type ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE869 | Confirmatory syphilis test type ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE466 | Type of treatment-limiting toxicity ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE681 | Cervical cancer triage test type ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE604 | Vaccine type ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE610 | Disease targeted ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.C.DE107 | Sex factor for estimating creatinine clearance ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE358 | Clinical stage at start of ART ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE186 | HIV clinical stage ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.C.DE11 | PrEP dosing type ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE61 | HIV exposure type ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE204 | Timing of adverse event ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.E.DE41 | Timing of ART initiation ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE142 | Counselling provided ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE56 | Antiretroviral (ARV) drugs received prior to enrolment ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.B.DE15 | Testing entry point ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.E.DE136 | Type of iron supplement dosage provided ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE43 | ART start type ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.E.DE108 | Infant or child exposure to HIV ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE391 | Reason for HIV viral load test ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE525 | Type of follow-up appointment ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.E.DE17 | Past pregnancy complications ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.D.DE1 | Reason for visit ValueSet | active | 2025-07 | |||
smart.who.int.hiv | R4 | ValueSet/HIV.C.DE143 | HIV self-test distributed for use by ValueSet | active | 2025-07 | |||
smart.who.int.immunizations | R4 | ValueSet/IMMZ.D2.DT.BCG | IMMZ.D2.DT.BCG ValueSet for Decision Table | active | 2025-08 | |||
smart.who.int.immunizations | R4 | ValueSet/IMMZ.D2.DT.Cholera.WC | IMMZ.D2.DT.Cholera.WC ValueSet for Decision Table | active | 2025-08 | |||
smart.who.int.immunizations | R4 | ValueSet/IMMZ.D2.DT.Cholera.rBS2to5 | IMMZ.D2.DT.Cholera.rBS2to5 ValueSet for Decision Table | active | 2025-08 | |||
smart.who.int.immunizations | R4 | ValueSet/IMMZ.D2.DT.Cholera.rBSover5 | IMMZ.D2.DT.Cholera.rBSover5 ValueSet for Decision Table | active | 2025-08 | |||
smart.who.int.immunizations | R4 | ValueSet/IMMZ.D2.DT.Dengue.NoScreen | IMMZ.D2.DT.Dengue.NoScreen ValueSet for Decision Table | active | 2025-08 | |||
smart.who.int.immunizations | R4 | ValueSet/IMMZ.D2.DT.Dengue.Seropos | IMMZ.D2.DT.Dengue.Seropos ValueSet for Decision Table | active | 2025-08 | |||
smart.who.int.immunizations | R4 | ValueSet/IMMZ.D2.DT.HepatitisA.IHAV1 | IMMZ.D2.DT.HepatitisA.IHAV1 ValueSet for Decision Table | active | 2025-08 | |||
smart.who.int.immunizations | R4 | ValueSet/IMMZ.D2.DT.HepatitisA.IHAV2 | IMMZ.D2.DT.HepatitisA.IHAV2 ValueSet for Decision Table | active | 2025-08 | |||
smart.who.int.immunizations | R4 | ValueSet/IMMZ.D2.DT.HepatitisA.LHAV1 | IMMZ.D2.DT.HepatitisA.LHAV1 ValueSet for Decision Table | active | 2025-08 |